Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

BACKGROUND: The open-label, randomized, active-controlled KEYNOTE-045 study (NCT02256436) showed that second-line pembrolizumab significantly improved overall survival (OS) of patients with advanced/metastatic urothelial cancer (UC) that progressed after first-line platinum-containing chemotherapy,...

詳細記述

保存先:
書誌詳細
出版年:Int J Clin Oncol
主要な著者: Nishiyama, Hiroyuki, Yamamoto, Yoshiaki, Sassa, Naoto, Nishimura, Kazuo, Fujimoto, Kiyohide, Fukasawa, Satoshi, Yokoyama, Minato, Enokida, Hideki, Takahashi, Kenichi, Tanaka, Yoshinobu, Imai, Kentaro, Shimamoto, Takashi, Perini, Rodolfo, Frenkl, Tara, Bajorin, Dean, Bellmunt, Joaquim
フォーマット: Artigo
言語:Inglês
出版事項: Springer Singapore 2019
主題:
Original Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6946746/
https://ncbi.nlm.nih.gov/pubmed/31729625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-019-01545-4
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料